目的:研究脂肪酸合成酶(FAS)抑制剂cerulenin对人胃癌细胞株增生的影响及诱导凋亡的作用.方法:MTT法观察终浓度2.5,5,10,20和40mg/Lcerulenin分别作用于无血清培养及含血清培养MKN28,SGC7901和MKN45细胞株24 h后,检测其对细胞增生的抑制作用.40 mg/L cerulenin作用于无血清培养的三种细胞12 h后,用流式细胞仪(FCM)、DNA凝胶电泳对其凋亡和细胞周期进行检测.结果:Cerulenin对人MKN28,SGC7901,MKN45细胞株的增生有显著的抑制作用并呈剂量依赖性,对无血清培养细胞株的抑制作用高于有血清组.2.5,5,10,20和40mg/Lcerulenin作用于有血清培养及无血清培养MKN28细胞24 h的抑制率分别为3.2±0.6%,7.3±0.5%,11.3±0.7%,17.7±1.2%,41.7±1.0%和5.1±1.3%,11.1±1.7%,20.9±1.3%,31.3±2.3%,60.2±3.9%,分别与其对照组比较有显著差异(1.4±1.3%,3.3±2.0%,6.2±3.2%,8.1±1.1%,10.1±1.7%,P＜0.05和2.8±1.1%,6.1±0.8%,8.5±1.3%,11.5±0.9%,17.2±2.2%,P＜0.05).2.5,5,10,20和40 mg/L cerulenin作用于有血清培养及无血清培养SGC7901细胞24 h的抑制率分别为3.4±0.8%,9.5±1.2%,23.3±1.7%,38.5±1.8%,65.2±2.1%和6.6±0.9%,14.3±2.1%,33.0±1.8%,56.9±2.2%,78.2±1.4%,与对照组比较有显著差异(2.3±1.0%,5.0±1.2%,7.3±1.0%,9.7±1.9%,13.4±1.3%,P＜0.05和3.9±1.2%,8.7±1.5%,10.5±1.9%,13.8±1.6%,19.5±1.7%,P＜0.05).2.5,5,10,20和40 mg/Lcerulenin作用于有血清培养及无血清培养MKN45细胞24h的抑制率分别为5.9±1.1%,13.5±0.9%,30.5±1.9%,49.1±1.5%,71.7±2.0%和8.4±1.1%,19.6±1.4%,40.4±1.4%,67.0±1.3%,83.8±2.0%,与对照组比较有显著差异(2.7±1.4%,7.4±1.1%,9.6±1.3%,12.6±1.1%,16.7±2.2%,P＜0.05和4.4±1.6%,9.5±0.9%,13.7±0.7%,18.4±1.6%,26.6±2.1%,P＜.05).Cerulenin
作用无血清培养MKN28,SGC7901,MKN45细胞株24 h的IC50值分别为13.3 mg/L,16.7 mg/L,32.3 mg/L显著低于含血清组(20.1 mg/L,26.6 mg/L,46.3 mg/L,P＜0.01).MKN28,SGC7901,MKN45细胞在Cerulenin(40 mg/L,12 h)作用下,凋亡率分别为10.1±0.7%,12.5±0.4%,14.9±0.8%,与对照组比较有显著差异(1.0±0.2%,0.9±0.5%,0.9±0.7%,P＜0.01),并引起胃癌细胞发生G2/M期阻滞.DNA凝胶电泳出现梯状条带.结论Cerulenin显著地阻遏人胃癌细胞的增生并诱导人胃癌细胞凋亡,是胃癌治疗的新靶点.
目的:研究脂肪痠閤成酶(FAS)抑製劑cerulenin對人胃癌細胞株增生的影響及誘導凋亡的作用.方法:MTT法觀察終濃度2.5,5,10,20和40mg/Lcerulenin分彆作用于無血清培養及含血清培養MKN28,SGC7901和MKN45細胞株24 h後,檢測其對細胞增生的抑製作用.40 mg/L cerulenin作用于無血清培養的三種細胞12 h後,用流式細胞儀(FCM)、DNA凝膠電泳對其凋亡和細胞週期進行檢測.結果:Cerulenin對人MKN28,SGC7901,MKN45細胞株的增生有顯著的抑製作用併呈劑量依賴性,對無血清培養細胞株的抑製作用高于有血清組.2.5,5,10,20和40mg/Lcerulenin作用于有血清培養及無血清培養MKN28細胞24 h的抑製率分彆為3.2±0.6%,7.3±0.5%,11.3±0.7%,17.7±1.2%,41.7±1.0%和5.1±1.3%,11.1±1.7%,20.9±1.3%,31.3±2.3%,60.2±3.9%,分彆與其對照組比較有顯著差異(1.4±1.3%,3.3±2.0%,6.2±3.2%,8.1±1.1%,10.1±1.7%,P＜0.05和2.8±1.1%,6.1±0.8%,8.5±1.3%,11.5±0.9%,17.2±2.2%,P＜0.05).2.5,5,10,20和40 mg/L cerulenin作用于有血清培養及無血清培養SGC7901細胞24 h的抑製率分彆為3.4±0.8%,9.5±1.2%,23.3±1.7%,38.5±1.8%,65.2±2.1%和6.6±0.9%,14.3±2.1%,33.0±1.8%,56.9±2.2%,78.2±1.4%,與對照組比較有顯著差異(2.3±1.0%,5.0±1.2%,7.3±1.0%,9.7±1.9%,13.4±1.3%,P＜0.05和3.9±1.2%,8.7±1.5%,10.5±1.9%,13.8±1.6%,19.5±1.7%,P＜0.05).2.5,5,10,20和40 mg/Lcerulenin作用于有血清培養及無血清培養MKN45細胞24h的抑製率分彆為5.9±1.1%,13.5±0.9%,30.5±1.9%,49.1±1.5%,71.7±2.0%和8.4±1.1%,19.6±1.4%,40.4±1.4%,67.0±1.3%,83.8±2.0%,與對照組比較有顯著差異(2.7±1.4%,7.4±1.1%,9.6±1.3%,12.6±1.1%,16.7±2.2%,P＜0.05和4.4±1.6%,9.5±0.9%,13.7±0.7%,18.4±1.6%,26.6±2.1%,P＜.05).Cerulenin
作用無血清培養MKN28,SGC7901,MKN45細胞株24 h的IC50值分彆為13.3 mg/L,16.7 mg/L,32.3 mg/L顯著低于含血清組(20.1 mg/L,26.6 mg/L,46.3 mg/L,P＜0.01).MKN28,SGC7901,MKN45細胞在Cerulenin(40 mg/L,12 h)作用下,凋亡率分彆為10.1±0.7%,12.5±0.4%,14.9±0.8%,與對照組比較有顯著差異(1.0±0.2%,0.9±0.5%,0.9±0.7%,P＜0.01),併引起胃癌細胞髮生G2/M期阻滯.DNA凝膠電泳齣現梯狀條帶.結論Cerulenin顯著地阻遏人胃癌細胞的增生併誘導人胃癌細胞凋亡,是胃癌治療的新靶點.
목적:연구지방산합성매(FAS)억제제cerulenin대인위암세포주증생적영향급유도조망적작용.방법:MTT법관찰종농도2.5,5,10,20화40mg/Lcerulenin분별작용우무혈청배양급함혈청배양MKN28,SGC7901화MKN45세포주24 h후,검측기대세포증생적억제작용.40 mg/L cerulenin작용우무혈청배양적삼충세포12 h후,용류식세포의(FCM)、DNA응효전영대기조망화세포주기진행검측.결과:Cerulenin대인MKN28,SGC7901,MKN45세포주적증생유현저적억제작용병정제량의뢰성,대무혈청배양세포주적억제작용고우유혈청조.2.5,5,10,20화40mg/Lcerulenin작용우유혈청배양급무혈청배양MKN28세포24 h적억제솔분별위3.2±0.6%,7.3±0.5%,11.3±0.7%,17.7±1.2%,41.7±1.0%화5.1±1.3%,11.1±1.7%,20.9±1.3%,31.3±2.3%,60.2±3.9%,분별여기대조조비교유현저차이(1.4±1.3%,3.3±2.0%,6.2±3.2%,8.1±1.1%,10.1±1.7%,P＜0.05화2.8±1.1%,6.1±0.8%,8.5±1.3%,11.5±0.9%,17.2±2.2%,P＜0.05).2.5,5,10,20화40 mg/L cerulenin작용우유혈청배양급무혈청배양SGC7901세포24 h적억제솔분별위3.4±0.8%,9.5±1.2%,23.3±1.7%,38.5±1.8%,65.2±2.1%화6.6±0.9%,14.3±2.1%,33.0±1.8%,56.9±2.2%,78.2±1.4%,여대조조비교유현저차이(2.3±1.0%,5.0±1.2%,7.3±1.0%,9.7±1.9%,13.4±1.3%,P＜0.05화3.9±1.2%,8.7±1.5%,10.5±1.9%,13.8±1.6%,19.5±1.7%,P＜0.05).2.5,5,10,20화40 mg/Lcerulenin작용우유혈청배양급무혈청배양MKN45세포24h적억제솔분별위5.9±1.1%,13.5±0.9%,30.5±1.9%,49.1±1.5%,71.7±2.0%화8.4±1.1%,19.6±1.4%,40.4±1.4%,67.0±1.3%,83.8±2.0%,여대조조비교유현저차이(2.7±1.4%,7.4±1.1%,9.6±1.3%,12.6±1.1%,16.7±2.2%,P＜0.05화4.4±1.6%,9.5±0.9%,13.7±0.7%,18.4±1.6%,26.6±2.1%,P＜.05).Cerulenin
작용무혈청배양MKN28,SGC7901,MKN45세포주24 h적IC50치분별위13.3 mg/L,16.7 mg/L,32.3 mg/L현저저우함혈청조(20.1 mg/L,26.6 mg/L,46.3 mg/L,P＜0.01).MKN28,SGC7901,MKN45세포재Cerulenin(40 mg/L,12 h)작용하,조망솔분별위10.1±0.7%,12.5±0.4%,14.9±0.8%,여대조조비교유현저차이(1.0±0.2%,0.9±0.5%,0.9±0.7%,P＜0.01),병인기위암세포발생G2/M기조체.DNA응효전영출현제상조대.결론Cerulenin현저지조알인위암세포적증생병유도인위암세포조망,시위암치료적신파점.
